Development of a Risk Prediction Model for Carbapenem-resistant Enterobacteriaceae Infection After Liver Transplantation: A Multinational Cohort Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
16 08 2021
Historique:
received: 06 11 2020
pubmed: 11 2 2021
medline: 23 9 2021
entrez: 10 2 2021
Statut: ppublish

Résumé

Patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) are at higher risk of developing CRE infection after liver transplantation (LT), with associated high morbidity and mortality. Prediction model for CRE infection after LT among carriers could be useful to target preventive strategies. Multinational multicenter cohort study of consecutive adult patients underwent LT and colonized with CRE before or after LT, from January 2010 to December 2017. Risk factors for CRE infection were analyzed by univariate analysis and by Fine-Gray subdistribution hazard model, with death as competing event. A nomogram to predict 30- and 60-day CRE infection risk was created. A total of 840 LT recipients found to be colonized with CRE before (n = 203) or after (n = 637) LT were enrolled. CRE infection was diagnosed in 250 (29.7%) patients within 19 (interquartile range [IQR], 9-42) days after LT. Pre- and post-LT colonization, multisite post-LT colonization, prolonged mechanical ventilation, acute renal injury, and surgical reintervention were retained in the prediction model. Median 30- and 60-day predicted risk was 15% (IQR, 11-24) and 21% (IQR, 15-33), respectively. Discrimination and prediction accuracy for CRE infection was acceptable on derivation (area under the curve [AUC], 74.6; Brier index, 16.3) and bootstrapped validation dataset (AUC, 73.9; Brier index, 16.6). Decision-curve analysis suggested net benefit of model-directed intervention over default strategies (treat all, treat none) when CRE infection probability exceeded 10%. The risk prediction model is freely available as mobile application at https://idbologna.shinyapps.io/CREPostOLTPredictionModel/. Our clinical prediction tool could enable better targeting interventions for CRE infection after transplant.

Sections du résumé

BACKGROUND
Patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) are at higher risk of developing CRE infection after liver transplantation (LT), with associated high morbidity and mortality. Prediction model for CRE infection after LT among carriers could be useful to target preventive strategies.
METHODS
Multinational multicenter cohort study of consecutive adult patients underwent LT and colonized with CRE before or after LT, from January 2010 to December 2017. Risk factors for CRE infection were analyzed by univariate analysis and by Fine-Gray subdistribution hazard model, with death as competing event. A nomogram to predict 30- and 60-day CRE infection risk was created.
RESULTS
A total of 840 LT recipients found to be colonized with CRE before (n = 203) or after (n = 637) LT were enrolled. CRE infection was diagnosed in 250 (29.7%) patients within 19 (interquartile range [IQR], 9-42) days after LT. Pre- and post-LT colonization, multisite post-LT colonization, prolonged mechanical ventilation, acute renal injury, and surgical reintervention were retained in the prediction model. Median 30- and 60-day predicted risk was 15% (IQR, 11-24) and 21% (IQR, 15-33), respectively. Discrimination and prediction accuracy for CRE infection was acceptable on derivation (area under the curve [AUC], 74.6; Brier index, 16.3) and bootstrapped validation dataset (AUC, 73.9; Brier index, 16.6). Decision-curve analysis suggested net benefit of model-directed intervention over default strategies (treat all, treat none) when CRE infection probability exceeded 10%. The risk prediction model is freely available as mobile application at https://idbologna.shinyapps.io/CREPostOLTPredictionModel/.
CONCLUSIONS
Our clinical prediction tool could enable better targeting interventions for CRE infection after transplant.

Identifiants

pubmed: 33564840
pii: 6132093
doi: 10.1093/cid/ciab109
doi:

Substances chimiques

Anti-Bacterial Agents 0
Carbapenems 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e955-e966

Investigateurs

Michele Bartoletti (M)
Renato Pascale (R)
Caterina Campoli (C)
Simona Coladonato (S)
Francesco Cristini (F)
Fabio Tumietto (F)
Antonio Siniscalchi (A)
Cristiana Laici (C)
Simone Ambretti (S)
Renato Romagnoli (R)
Francesco Giuseppe De Rosa (FG)
Antonio Muscatello (A)
Davide Mangioni (D)
Andrea Gori (A)
Barbara Antonelli (B)
Daniele Dondossola (D)
Giorgio Rossi (G)
Federica Invernizzi (F)
Maddalena Peghin (M)
Umberto Cillo (U)
Cristina Mussini (C)
Fabrizio Di Benedetto (FD)
Débora Raquel Benedita Terrabuio (DRB)
Carolina D Bittante (CD)
Alexandra do Rosário Toniolo (ADR)
Elizabeth Balbi (E)
José Huygens Parente Garcia (JHP)
Ignacio Morrás (I)
Antonio Ramos (A)
Ana Fernandez Cruz (AF)
Magdalena Salcedo (M)

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Maddalena Giannella (M)

Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Maristela Freire (M)

Working Committee for Hospital Epidemiology and Infection Control, Hospital das Clinicas, Universidade de São Paulo, São Paulo, Brazil.

Matteo Rinaldi (M)

Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Edson Abdala (E)

Infectious Diseases Department, Hospital das Clinicas, Universidade de São Paulo, São Paulo, Brazil.

Arianna Rubin (A)

Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.

Alessandra Mularoni (A)

Infectious Diseases, ISMETT IRCCS, Palermo, Italy.

Salvatore Gruttadauria (S)

Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, IRCCS, ISMETT-UPMC, Palermo, Italy.

Paolo Grossi (P)

Infectious and Tropical Diseases Department, University of Insubria, Varese, Italy.

Nour Shbaklo (N)

Infectious Disease, Department of Medical Sciences University of Turin AOU Città della salute e della Scienza, Turin, Italy.

Francesco Tandoi (F)

Liver Transplant Center, General Surgery Unit, Department of Surgical Sciences, AOU Città della Salute e della Scienza, Molinette Hospital, University of Turin, Turin, Italy.

Alberto Ferrarese (A)

Multivisceral Transplant Unit (Gastroenterology), Department of Surgery Oncology and Gastroenterology, Surgical and Gastroenterological Sciences, Padua University Hospital, Padua, Italy.

Patrizia Burra (P)

Multivisceral Transplant Unit (Gastroenterology), Department of Surgery Oncology and Gastroenterology, Surgical and Gastroenterological Sciences, Padua University Hospital, Padua, Italy.

Ruan Fernandes (R)

Infectious Diseases Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Luis Fernando Aranha Camargo (LF)

Infectious Diseases Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Angel Asensio (A)

Preventive Medicine Department, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, Madrid, Spain.

Laura Alagna (L)

Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Alessandra Bandera (A)

Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Jacques Simkins (J)

Transplant Infectious Diseases and Immunocompromised Host Service, Division of Infectious Diseases, University of Miami/Miami Transplant Institute, Miami, Florida, USA.

Lilian Abbo (L)

Department of Medicine, Division of Infectious Diseases, University of Miami, Miami, Florida, USA.

Marcia Halpern (M)

Liver Transplant Unit, Quinta D'Or Hospital, Rio de Janeiro, Brazil.

Evelyne Santana Girao (E)

Infectious Diseases Unit and Liver Transplant Unit of Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brazil.

Maricela Valerio (M)

Department of Clinical Microbiology and Infectious Diseases, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Patricia Muñoz (P)

Department of Clinical Microbiology and Infectious Diseases, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Ainhoa Fernandez Yunquera (A)

Department of Gastroenterology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Liran Statlender (L)

Intensive Care Unit, Rabin Medical Center, Petah Tikva, Israel.

Dafna Yahav (D)

Infectious Disease Unit, Beilinson Hospital, Petah Tikva, Israel.

Erica Franceschini (E)

Infectious Diseases Unit, Department of Nephrology Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy.

Elena Graziano (E)

Infectious Disease Clinic, ASUFC, Udine, Italy.

Maria Cristina Morelli (MC)

Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.

Matteo Cescon (M)

Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Liver and Multiorgan Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.

Pierluigi Viale (P)

Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Russell Lewis (R)

Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH